Mometasone furoate; olopatadine hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for mometasone furoate; olopatadine hydrochloride and what is the scope of freedom to operate?
Mometasone furoate; olopatadine hydrochloride
is the generic ingredient in one branded drug marketed by Glenmark Specialty and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Mometasone furoate; olopatadine hydrochloride has eighty-eight patent family members in thirty-two countries.
One supplier is listed for this compound.
Summary for mometasone furoate; olopatadine hydrochloride
International Patents: | 88 |
US Patents: | 14 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 2 |
DailyMed Link: | mometasone furoate; olopatadine hydrochloride at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for mometasone furoate; olopatadine hydrochloride
Generic Entry Date for mometasone furoate; olopatadine hydrochloride*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT Dosage:
SPRAY, METERED;NASAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for mometasone furoate; olopatadine hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Glenmark Specialty S.A. | Phase 3 |
Glenmark Pharmaceuticals Ltd. India | Phase 2 |
See all mometasone furoate; olopatadine hydrochloride clinical trials
Pharmacology for mometasone furoate; olopatadine hydrochloride
Drug Class | Corticosteroid Histamine-1 Receptor Antagonist Histamine-1 Receptor Inhibitor Mast Cell Stabilizer |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists Histamine H1 Receptor Antagonists |
Physiological Effect | Decreased Histamine Release |
US Patents and Regulatory Information for mometasone furoate; olopatadine hydrochloride
International Patents for mometasone furoate; olopatadine hydrochloride
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2017206560 | モメタゾン及びオロパタジンを有する安定な定用量薬剤組成物 (STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE) | ⤷ Try a Trial |
China | 111787954 | 使用莫美他松和奥洛他定的组合治疗儿科受试者的过敏性鼻炎 (TREATMENT OF ALLERGIC RHINITIS IN PEDIATRIC SUBJECTS USING A COMBINATION OF MOMETASONE AND OLOPATADINE) | ⤷ Try a Trial |
Brazil | 112015018252 | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | ⤷ Try a Trial |
Russian Federation | 2687551 | СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С ФИКСИРОВАННОЙ ДОЗОЙ, СОДЕРЖАЩАЯ МОМЕТАЗОН И ОЛОПАТАДИН (STABLE PHARMACEUTICAL COMPOSITION WITH FIXED DOSE, CONTAINING MOMETASONE AND OLOPATADINE) | ⤷ Try a Trial |
European Patent Office | 3755375 | TRAITEMENT DE LA RHINITE ALLERGIQUE CHEZ DES SUJETS PÉDIATRIQUES À L'AIDE D'UNE COMBINAISON DE MOMÉTASONE ET D'OLOPATADINE (TREATMENT OF ALLERGIC RHINITIS IN PEDIATRIC SUBJECTS USING A COMBINATION OF MOMETASONE AND OLOPATADINE) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for mometasone furoate; olopatadine hydrochloride
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3043773 | 21C1057 | France | ⤷ Try a Trial | PRODUCT NAME: MOMETASONE OU L'UN DE SES SELS AVEC OLOPATADINE OU L'UN DE SES SELS; NAT. REGISTRATION NO/DATE: NL52121 20211026; FIRST REGISTRATION: AT - 140638 20210426 |
3043773 | CA 2021 00050 | Denmark | ⤷ Try a Trial | PRODUCT NAME: MOMETASON ELLER ET SALT DERAF OG OLOPATADIN ELLER ET SALT DERAF; NAT. REG. NO/DATE: 63820 20210706; FIRST REG. NO/DATE: AT 140638 20210426 |
0112669 | 96C0002 | Belgium | ⤷ Try a Trial | PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622 |
3043773 | 57/2021 | Austria | ⤷ Try a Trial | PRODUCT NAME: MOMETASON ODER EIN SALZ DAVON UND OLOPATADIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: 140638 20210426 |
3043773 | 2022C/520 | Belgium | ⤷ Try a Trial | PRODUCT NAME: MOMETASONE OF EEN ZOUT HIERVAN EN OLOPATADINE OF EEN ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: BE595626 20220203 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.